Allergic Rhinitis Drugs Market Forecast 2016-2026

31 August 2016
Pharma

A new report by visiongain predicts that the Allergic Rhinitis Drugs market will reach $16,500m in 2026. This forecast and others appear in - Allergic Rhinitis Drugs Market Forecast 2016-2026: Analysis of the Current Trend and Pipeline Opportunities in the Intranasal Antihistamines, Intranasal Corticosteroids, Oral Antihistamines, and Immunotherapy and Vaccines Markets, Including Current Products such as Patanase, Dymista, Nasonex, Allegra, and Staloral with Assessment of Key Companies in the Allergic Rhinitis Market Including GSK and Merck & Co. published in September 2016. Visiongain is a business information provider based in London, UK.
The Allergic Rhinitis Drugs Market Forecast 2016-2026: Analysis of the Current Trend and Pipeline Opportunities in the Intranasal Antihistamines, Intranasal Corticosteroids, Oral Antihistamines, and Immunotherapy and Vaccines Markets, Including Current Products such as Patanase, Dymista, Nasonex, Allegra, and Staloral with Assessment of Key Companies in the Allergic Rhinitis Market Including GSK and Merck & Co., report examines the current and future trends in the Allergic Rhinitis Drugs Market with particular focus on recent pivotal developments in the sector involving patent expires, OTC swithces, launch of new drugs and pipeline products. These developments in addition to changes in population demographics are changing the landscape of the allergic rhinitis drugs market.

Allergic Rhinitis Drugs are used to treat and manage allergic rhinitis symptoms. This is irritation and inflammation of the lining of the nasal passages which is caused by an allergic reaction. The symptoms are sneezing, nasal congestions, itching and rhinorrhoea. Allergic Rhinitis is very common, leading to a large patient population.

The driving force behind growth in this market is the increasing prevalence of allergic rhinitis, new products launching onto the market and OTC switches. There is an increased demand for treatment of allergic rhinitis, as a result of climate change and industrialisation. The allergic rhinitis drugs market is increasingly expected to innovate in order to meet these demands in a safe manner, focusing intention on treatment rather than symptomatic relief.

In this report, we examine in detail the factors which are driving the Allergic Rhinitis Drugs Market growth, the key companies currently operating in the allergic rhinitis drugs market including their product pipelines. We also examine key national markets and discuss trends and variations within these markets, alongside an analysis of allergic rhinitis drugs.

The Allergic Rhinitis market segments examined in this report are: Intranasal Corticosteroids, Oral Antihistamines, Immunotherapy and Vaccines, Intranasal Antihistamines. National Markets focused on are the US, China, Japan, EU5 (Germany, UK, Italy, France and Spain), Brazil, Russia and India.

Using both primary and secondary research, forecasts have been built for the major submarkets, leading products and leading national and regional markets, accompanied by text giving a thorough explanation of events thought to shape the market currently and in the future.

Visiongain’s report also provides an analysis of the current leading players in the Allergic Rhinitis Drugs Market. Historical financial performance is analysed, along with a breakdown of each company’s leading products and pipeline research, and recent merger & acquisition information, with an analysis of news that may influence the course of the company.

Allergic Rhinitis Drugs Market Forecast 2016-2026: Analysis of the Current Trend and Pipeline Opportunities in the Intranasal Antihistamines, Intranasal Corticosteroids, Oral Antihistamines, and Immunotherapy and Vaccines Markets, Including Current Products such as Patanase, Dymista, Nasonex, Allegra, and Staloral with Assessment of Key Companies in the Allergic Rhinitis Market Including GSK and Merck & Co. adds to visiongain’s range of analytical reports on industries and markets in healthcare.

For an executive summary please contact:
Email: Sara Peerun on sara.peerun@visiongainglobal.com
Tel: +44 (0) 20 7336 6100

Notes for Editors

If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44 (0) 207 336 6100

About visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. From its head office in London, UK, visiongain produces a range of newsletters, business reports and e-zines covering current affairs and market trends in the Energy, Telecoms, Pharmaceutical, Defence, and Materials sectors.

Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high quality, original analyses to inform their strategic decisions.

Recent News

“Global Ophthalmic Drugs market set to grow to $32bn by 2024” says Visiongain report

Successful harnessing of the opportunities for growth in the ophthalmic pharmaceuticals market will depend upon the development of novel products with technologies that increase clinical effectiveness and development of products for previously-untreated ophthalmic conditions.

15 August 2019

Read

“Global Medical Device Contract Manufacturing market set to grow to $130bn by 2024” says new Visiongain report

The available reduced costs of outsourced manufacturing combined with access to the innovation power of CMOs are major drivers behind the decision to outsource manufacturing processes.

06 August 2019

Read

“3D Printing for Healthcare market is worth $872 million in 2019” says Visiongain report

The main appeal of 3D printed healthcare products to professionals is that each unit can be personalised to fit the recipient.

02 August 2019

Read

“Global Rare Disease Drugs market set to grow to $257bn by 2024” says new Visiongain report

It is difficult to investigate rare diseases as the pool of patients is very small and often results in inadequate clinical knowledge.

01 August 2019

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever